An Enhanced Scrutiny of Mechanistic and Translational Approaches to Extinguish Cancer Hypoxia.

Q2 Pharmacology, Toxicology and Pharmaceutics
Arun Radhakrishnan, Nikhitha K Shanmukhan, Linda Christabel S
{"title":"An Enhanced Scrutiny of Mechanistic and Translational Approaches to Extinguish Cancer Hypoxia.","authors":"Arun Radhakrishnan, Nikhitha K Shanmukhan, Linda Christabel S","doi":"10.2174/0122117385328105241216042016","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer continues to pose a formidable challenge in global health due to its incidence and increasing resistance to conventional therapies. A key factor driving this resistance is tumor hypoxia, characterized by reduced oxygen levels within cancer cells. This hypoxic environment triggers a variety of adaptive mechanisms, significantly compromising the efficacy of cancer treatments. Notably, hypoxia promotes metastasis and reshapes the tumor microenvironment (TME), thereby aggravating treatment resistance. Central to this process are hypoxia-inducible factors (HIFs), which mediate cellular adaptations such as metabolic shifts and enhanced survival pathways. These adaptations render therapies like chemotherapy, radiotherapy, and photodynamic therapy (PDT) less effective. Additionally, hypoxia-induced vascular irregularities further impede drug delivery, amplifying the therapeutic challenge. This review provides a comprehensive examination of the roles of hypoxia in cancer, its contributions to drug resistance, and its interplay with apoptosis and autophagy. By evaluating novel mechanistic and translational approaches to target hypoxia, this study highlights the potential to improve therapeutic outcomes and offers insights into overcoming treatment resistance in cancer.</p>","PeriodicalId":19774,"journal":{"name":"Pharmaceutical nanotechnology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0122117385328105241216042016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer continues to pose a formidable challenge in global health due to its incidence and increasing resistance to conventional therapies. A key factor driving this resistance is tumor hypoxia, characterized by reduced oxygen levels within cancer cells. This hypoxic environment triggers a variety of adaptive mechanisms, significantly compromising the efficacy of cancer treatments. Notably, hypoxia promotes metastasis and reshapes the tumor microenvironment (TME), thereby aggravating treatment resistance. Central to this process are hypoxia-inducible factors (HIFs), which mediate cellular adaptations such as metabolic shifts and enhanced survival pathways. These adaptations render therapies like chemotherapy, radiotherapy, and photodynamic therapy (PDT) less effective. Additionally, hypoxia-induced vascular irregularities further impede drug delivery, amplifying the therapeutic challenge. This review provides a comprehensive examination of the roles of hypoxia in cancer, its contributions to drug resistance, and its interplay with apoptosis and autophagy. By evaluating novel mechanistic and translational approaches to target hypoxia, this study highlights the potential to improve therapeutic outcomes and offers insights into overcoming treatment resistance in cancer.

加强对消除癌症缺氧的机制和转化方法的审查。
由于癌症的发病率和对常规疗法的抵抗力不断增强,癌症继续对全球健康构成巨大挑战。驱动这种抵抗的一个关键因素是肿瘤缺氧,其特征是癌细胞内氧水平降低。这种低氧环境触发了多种适应机制,显著影响了癌症治疗的效果。值得注意的是,缺氧促进转移和重塑肿瘤微环境(TME),从而加重治疗抵抗。这个过程的核心是缺氧诱导因子(hif),它介导细胞适应,如代谢变化和增强的生存途径。这些适应性使得化疗、放疗和光动力疗法(PDT)等疗法效果降低。此外,缺氧引起的血管不规则进一步阻碍了药物输送,增加了治疗挑战。本文综述了缺氧在肿瘤中的作用、对耐药的贡献以及与细胞凋亡和自噬的相互作用。通过评估靶向缺氧的新机制和转化方法,本研究强调了改善治疗结果的潜力,并为克服癌症治疗耐药提供了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical nanotechnology
Pharmaceutical nanotechnology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
4.20
自引率
0.00%
发文量
46
期刊介绍: Pharmaceutical Nanotechnology publishes original manuscripts, full-length/mini reviews, thematic issues, rapid technical notes and commentaries that provide insights into the synthesis, characterisation and pharmaceutical (or diagnostic) application of materials at the nanoscale. The nanoscale is defined as a size range of below 1 µm. Scientific findings related to micro and macro systems with functionality residing within features defined at the nanoscale are also within the scope of the journal. Manuscripts detailing the synthesis, exhaustive characterisation, biological evaluation, clinical testing and/ or toxicological assessment of nanomaterials are of particular interest to the journal’s readership. Articles should be self contained, centred around a well founded hypothesis and should aim to showcase the pharmaceutical/ diagnostic implications of the nanotechnology approach. Manuscripts should aim, wherever possible, to demonstrate the in vivo impact of any nanotechnological intervention. As reducing a material to the nanoscale is capable of fundamentally altering the material’s properties, the journal’s readership is particularly interested in new characterisation techniques and the advanced properties that originate from this size reduction. Both bottom up and top down approaches to the realisation of nanomaterials lie within the scope of the journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信